CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Abroad (travel likely)RecruitingPHASE2

Conditions

Acute Myeloid Leukemia With Gene Mutations · Myelodysplastic Syndrome · Myeloproliferative Neoplasm · Recurrent Acute Myeloid Leukemia · Refractory Acute Myeloid Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

M D Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Courtney DiNardo, MD) · cdinardo@mdanderson.org · 713-794-1141
Contact: Principal Investigator (Courtney DiNardo, MD)

Study leads

Courtney DiNardo, MD
Principal Investigator
M.D. Anderson Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Acute Myeloid Leukemia · Blasts 20-30 Percent of Bone Marrow Nucleated Cells · Chronic Myelomonocytic Leukemia

Abroad (travel likely)RecruitingPHASE2

Baltimore, United States · Cleveland, United States

a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia

Acute Myeloid Leukemia · IDH1 Gene Mutation · Ivosidenib

Abroad (travel likely)RecruitingPHASE2

Suzhou, China

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE3

Birmingham, United States · Mobile, United States

Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

Germline Mutation · Myelodysplastic Syndromes · Acute Myeloid Leukemia

Abroad (travel likely)Recruiting

Bethesda, United States